Clinical Trial Update: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy [Phase 3]

View source ↗

Summary

This is a Phase III multicenter, randomized, double-blind trial evaluating HRS9531 injection for obstructive sleep apnea in patients with obesity who are on PAP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obstructive Sleep Apnea

Drugs mentioned

• HRS9531 Injection (HRS9531)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | Phase 3 | Status: RECRUITING